

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8230277

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MITSUBISHI TANABE PHARMA CORPORATION	10/10/2023
RECEIVING PARTY DATA	
Name:	OSAKA UNIVERSITY
Street Address:	1-1, YAMADAOKA
City:	SUITA-SHI, OSAKA
State/Country:	JAPAN
Postal Code:	565-0871
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17518212
CORRESPONDENCE DATA	
Fax Number:	(312)616-5700
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(312)616-5600
Email:	arosales@leydig.com, assignments@leydig.com
Correspondent Name:	LEYDIG, VOIT & MAYER, LTD.
Address Line 1:	TWO PRUDENTIAL PLAZA, SUITE 4900
Address Line 2:	180 NORTH STETSON AVENUE
Address Line 4:	CHICAGO, ILLINOIS 60601-6745
ATTORNEY DOCKET NUMBER:	758140
NAME OF SUBMITTER:	JOHN KILYK, JR.
SIGNATURE:	/John Kilyk, Jr./
DATE SIGNED:	10/19/2023
Total Attachments: 1	
source=Assignment - Mitsubishi Tanabe to Osaka University#page1.tif	

ASSIGNMENT

WHEREAS, MITSUBISHI TANABE PHARMA CORPORATION, 3-2-10, Doshomachi, Chuo-ku, Osaka-shi, Osaka 541-8505 Japan, hereinafter referred to as Assignor, co-owns, along with OSAKA UNIVERSITY, U.S. Patent Application No. 17/518,212, which was filed on November 3, 2021, and is entitled "NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE" having been assigned its right, title and interest in the invention by virtue of an Assignment recorded at the U.S. Patent and Trademark Office on December 30, 2021, at Reel 058509, Frame 0630, and

WHEREAS, OSAKA UNIVERSITY, of 1-1, Yamadaoka, Suita-shi, Osaka 565-0871 Japan, hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest of Assignor in, to, and under U.S. Patent Application No. 17/518,212,

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor sells, assigns and transfers to the Assignee and the Assignee's legal representatives, successors, and assigns the entire right, title, and interest of Assignor in, to, and under U.S. Patent Application No. 17/518,212, including any U.S. patent issuing therefrom and any U.S. patent applications and U.S. patents claiming priority thereto (e.g., continuations, continuations-in-part, and divisionals), as well as any reissues, reexaminations, and other revisions thereof as may result from post-issuance proceedings, including post-grant reviews and inter partes reviews thereof,

Assignor hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

Assignor will not execute any writing or do any act conflicting with the terms of this Assignment, and Assignor will, upon request and at Assignee's expense, execute such additional documents and do such additional acts as may be necessary to perfect the Assignee's enjoyment of this Assignment,


The terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has caused one of its duly authorized officers or representatives to hereunder set his/her hand on the date shown below.

Date Oct 10, 2023



Printed Name: Junko Iyoda
Title: Senior Director, Head of Pharma IP Department
MITSUBISHI TANABE PHARMA CORPORATION